logo

For the Inventor, By the Inventor

Jerusalem, Israel

Clexio Biosciences Ltd.


USPTO Granted Patents = 36

% Expired Patents = 5.6



Trademarks = 1

Forward Citations = 75

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Ilan Zalit (9 out of 9 patents)

silverMedal Elena Kagan (9 out of 9 patents)

bronzeMedal Avshalom Ben Menachem (9 out of 9 patents)

4.  Derek V Moe (9 out of 20 patents)

5.  Gina Pastino (7 out of 7 patents)

6.  Dinesh K Haswani (6 out of 10 patents)

7.  Manuel A Vega Zepeda (6 out of 14 patents)

8.  Randal A Seburg (6 out of 8 patents)

9.  Victoria Ann O'Neill (6 out of 19 patents)

10.  Richard Fisher (4 out of 4 patents)

11.  David Dangoor (4 out of 4 patents)

12.  Sagar Rane (3 out of 3 patents)

13.  Yael Rosen (3 out of 3 patents)

14.  Johanna Schumann (2 out of 2 patents)

15.  Dorit Mimrod (2 out of 2 patents)


Core Competencies:
Esketamine
Abuse-Deterrent
Gastroretentive
Dosage Forms
Major Depressive Disorder
Pruritus
Long Acting
Transdermal
Gastric Residence
Immediate Release
Expandable
Fibrous Structures

36 patents:

1. 12589083 - Abuse-deterrent dosage forms containing esketamine (2026-03-31),
2. 12514831 - Method of treating major depressive disorder (2026-01-06),
3. 12478592 - Dosage regime with esketamine for treating neuropsychiatric or neurological conditions (2025-11-25),
4. 12364672 - Esketamine for use in treating major depressive disorder (2025-07-22),
5. 12336970 - Method of treating major depressive disorder (2025-06-24),
6. 12280022 - Method of treating major depressive disorder (2025-04-21),
7. 12268658 - Dosage regime with esketamine for treating major depressive disorder (2025-04-08),
8. 12239634 - Methods of treating pruritus (2025-03-04),
9. 12076300 - Dosage regime with esketamine for treating major depressive disorder (2024-09-03),
10. 12036189 - Method of treating major depressive disorder (2024-07-16),
11. 12016832 - Method of treating major depressive disorder (2024-06-25),
12. 11992468 - Abuse-deterrent dosage forms containing esketamine (2024-05-28),
13. 11964120 - Long acting gastric residence system (2024-04-23),
14. 11957645 - Method of treating major depressive disorder (2024-04-16),
15. 11903928 - Methods of treating pruritus (2024-02-20),
Company Overview
Clexio Biosciences Ltd. is a biotechnology company based in Jerusalem, Israel, focused on advancing therapeutic solutions through innovative bioscience research. The organization specializes in the development of novel biopharmaceuticals, leveraging cutting-edge technologies to address unmet medical needs. Clexio's research encompasses various domains, including drug discovery and development, with an emphasis on harnessing biological processes to create effective treatments. The company is committed to improving patient outcomes through scientific excellence and collaboration.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

36 Patents

#7 in Jerusalem

#152 in Israel

#18,716 in the World

Jerusalem, IL
Jerusalem, Israel

Clexio Biosciences Ltd.

Forward Citations = 75

25 inventors:

goldMedal Ilan Zalit (9 out of 9 patents)

silverMedal Elena Kagan (9 out of 9 patents)

bronzeMedal Avshalom Ben Menachem (9 out of 9 patents)

4.  Derek V Moe (9 out of 20 patents)

5.  Gina Pastino (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Clexio Biosciences Ltd.. Retrieved from https://idiyas.com/company/clexio-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Please report any incorrect information to [email protected]
Loading…